Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease Patients Under the Age of 6 Years
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Registrational; Therapeutic Use
- Acronyms WIL-33
- Sponsors Octapharma
- 19 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Dec 2024.
- 19 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Dec 2024.
- 23 Aug 2023 Planned End Date changed from 1 Aug 2024 to 1 Oct 2023.